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ABSTRACT  
Background: Brassica carinata is one of the traditional medicinal plants used in Ethiopia for 
treatment of wound and other diseases. Although there are many reports in the literature 
about brassica vegetables, only a few is studied about B. carinata and nothing has so far been 
reported about the wound healing activity of this plant. Thus, this work was initiated to 
investigate the wound healing activities of the seeds of B. carinata in mice. 
Objective: To evaluate wound healing activities of 80% methanol extract and solvent 
fractions of seed of B. carinata A Braun in mice 
 Methods: Following extraction of the seeds of the plant with 80 % methanol, the extract was 
formulated as ointments (5% and 10% w/w). Then, it was evaluated for wound healing 
activity in excision and incision models. Wound contraction, epithelialization and breaking 
strength were parameters. Then, fractionation took place to further evaluate solvent fractions.  
To explore antibacterial activity as one possible mechanism for wound healing, the crude 
extract was subjected to agar well diffusion assay. Briefly, Muller Hilton agar was prepared, 
dispensed to plates and incubated at 37⁰C for 24 h for sterility testing. After bacteria were 
streaked, wells were created and antibiotic discs as positive control, distilled water as 
negative control and 100 μl extract of 125, 250 and 500mg/ml concentrations were filled. 
Then, plates were incubated at 37⁰C for 24 h to measure zone of inhibition. Finally, 
phytochemical tests were done to evaluate the presence of secondary metabolites. 
Results:  Both 5 % and 10 % (w/w) extracts exhibited significant wound healing activity in a 
concentration dependent manner in both models as compared to the negative control. All the 
fractions showed significant wound healing activity in excision model. The crude extract 
didn’t exhibit antibacterial activity. Phytochemical analysis revealed positive for 
polyphenols, alkaloids, flavonoids, saponins, tannins, glycosides and steroids, but negative 
for terpinoids. 
Conclusion: In the present study B. carinata crude extract and solvent fractions showed good 
wound healing activity, and the aqueous fraction showed better wound healing activity than 
the crude extracts as well as other fractions.  
Key words: wound contraction, epithelialization, tensile strength, incision, excision, Brassica 
carinata
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1. INTRODUCTION 
1.1 Back ground  
The skin is the largest organ and protects the body from the external environment such as 
dehydration, radiation, environmental aggressions and  functions as first line defense against 
pathogens (1). The skin can be broken as a result of trauma due to abrasions, lacerations, and 
thermal, electrical, or chemical burns, etc(2). The most common definition of wound is “loss 
or breaking of cellular and anatomic or functional continuity of living tissues”(3, 4). 
Wounds can be broadly categorized as acute or chronic wound. An acute wound involves 
normal inflammatory stages without underlying pathology and usually heals without 
complications within short duration of time. Whereas chronic wounds involve prolonged 
inflammatory stage with underlying pathology that are usually unhealed within 6 weeks of 
formation and result in variety of complications(5). All wound types have the potential to 
become chronic unless proper management was sought as early as possible and chronic 
wounds are classified by cause. Venous or arterial insufficiency, diabetes, obesity and local 
pressure effects are the most common pathophysiological causes (6).  
1.2 Epidemiology and cost of wound healing  
In the United States, around 6.5 million patients suffered from chronic wounds that cost 
US$25 billion per year and the burden is growing rapidly due to increasing health care costs, 
an aging population and a sharp rise in the incidence of diabetes and obesity worldwide. The 
annual wound care products market is projected to reach $15.3 billion by 2010. Diabetes and 
obesity patients frequently suffer from chronic wound. The increasing  economic and social 
impact of wounds necessitates  a higher level of attention and resources to be allocated to 
understand biological mechanisms underlying cutaneous wound complications (7). 
In United Kingdom, around 200,000 chronic wounds costs an estimated £2.03 Million 
annually per 100,000 populations, based on 2006-2007 prices (8). 
In addition, there are a large number of acute wounds and increase wound burden in the 
society.  It is estimated that greater than 5 million people suffer from acute wounds, of which 
greater than 1.25 million people have burns. Complications of wound are numerous unless an 
acute wound heals in an orderly and timely manner (9). 
Wound due to trauma is a very common problem in developing countries. Psychosocial 
outcomes and physical health outcomes comprise the majority costs of trauma in sub-Saharan 
Africa (10).   
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Even though, there are no much data concerning the current status of wound problem in 
Ethiopia, it is a common health problem of the community as well.  
 The prevalence of chronic wounds in sub-Saharan Africa was reported as 4.5 per 1000 
population, whereas that of acute wounds was 10.5 per 1,000 populations. Patients older than 
60 years are the most frequently affected (11). 
Patients face numerous direct and indirect medical costs. Psychosocial and physical health 
outcomes comprise the main health outcomes of trauma and wound. Some of the 
complications of wound include disability that results in lost wages, decreased productivity 
and a diminished quality of life. Cellulites, abscess formation, osteomyelitis, gangrene and 
even sepsis may occur as a result of an infected wound. Furthermore, chronic wounds have 
the potential for malignant transformation (12).  
1.3 Wound healing physiology 
Wound healing involves a sequence of events which consists of coagulation, inflammation, 
granulation, wound contraction, epithelialization, and collagenation and collagen maturation 
to final scar tissue formation. Each process of wound healing is characterized by unique 
physiologic responses which are concurrent but independent to each other (13). 
Inflammatory phase 
During this phase, the process starts with blood clotting; initially there is constriction of the 
blood vessels for blood clotting followed by platelet aggregation and formation of a scab. 
Haemostasis is followed by inflammatory phase that is characterized by increased capillary 
permeability and migration of inflammatory cells to the affected area with the aim to cleanse 
the wound.  Many substances in the injured area, such as fibrin degradation products, 
leukotrienes, complement products, bacterial peptides, and PDGF and TGF that have been 
released from platelets, act as general leukocyte attractant mediators that support the 
recruitment of leukocytes. The inflammatory response increase vascular permeability 
resulting in migration of neutrophils and monocytes into the surrounding tissue. The 
neutrophils engulf debris and microorganisms, providing the first line of defense against 
infection. Neutrophils migration ceases after the few days’ post injury if the wound is not 
contaminated (14).  In the late inflammatory phase, monocytes converted in the tissue to 
macrophages which digest and kill bacterial pathogens, scavenge tissue debris and destroy 
remaining neutrophils. Macrophages begin the transition from wound inflammation to wound 
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repair by secreting a variety of chemotactic and growth factors that stimulate cell migration, 
proliferation and formation of the tissue matrix(15).  
Proliferative phase 
The subsequent proliferative phase is dominated by the formation of granulation tissue and 
epithelialization. During granulation, new collagen tissue is laid down, and new capillaries 
fill in the defect. Wound contraction also occurs when the wound edges pull together. In 
epithelialization, cells cross over the moist surface. Chemo tactic and growth factors released 
from platelets and macrophages stimulate the migration and activation of wound fibroblasts 
(15). Early in the proliferation phase fibroblast activity is limited to cellular replication and 
migration. Fibroblasts themselves secrete a variety of cytokines, allowing other vital cells to 
proliferate and aid the healing process. Such cells include endothelial cells and angiocytes. 
Expansion of these cell numbers contributes to a process known as angiogenesis, the 
generation of new blood vessels (16). Later, fibroblast cells begin to synthesize and secret 
measurable amounts of collagen. Collagen levels rise continually for approximately three 
weeks. The amount of collagen secreted during this period determines the tensile strength of 
the wound (13). 
Re-epithelization and granulation tissue formation during repair are mediated by a wide 
variety of growth and differentiation factors(17).  Platelet derived growth factor is the 
principal inducer of matrix proteins that are important for creating the provisional matrix that 
initially fills the void created by tissue damage. Transforming growth factor- β (TGF- β 1, - β 
2, and- β 3), produced by macrophages during the early phase of wound healing, mediates the 
chemotaxis of monocytes, lymphocytes, polymorphonuclear neutrophils and fibroblasts. It is 
also a potent stimulant of ECM production in vivo and is involved in the synthesis of 
collagen by fibroblasts. Fibroblast growth factors are the major growth factor family involved 
in angiogenesis, directing endothelial cell migration, proliferation and plasminogen activator 
synthesis. Vascular endothelial growth factors promote angiogenesis. Insulin/(insulin like 
growth factor1 has been shown to produce favorable effects on wound healing by enhanced 
tensile strength, increased hydroxyl proline content and enhanced grade of cellular 
immunity(18-21).  
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Remodeling phase:  
It involves a reorganization of new collagen fibers, forming a more organized lattice structure 
that progressively continues to increase wound tensile strength. After the main steps of the 
proliferative phase are fulfilled, the density of cells, such as macrophages, keratinocytes, 
fibroblasts and myofibroblasts is reduced by apoptosis. Keratinocytes are the first cells to 
undergo programmed cell death; myofibroblasts are the second so that the accelerated 
proliferation and migration normalizes. Gradually, the provisional collagen (type III initial 
new collagen synthesized in the proliferative phase) is replaced by the more stable collagen 
type I that is produced strictly oxygen dependently by fibroblasts and is deposited in a 
physiological alignment. The healing wound gains increased wound tensile strength(22). The 
collagen fibers contract so that the wound tissue shrinks. The remodeling process continues 
up to two years, achieving 40-70 percent of the strength of undamaged tissue at four 
weeks(13). In healthy adults, type I collagen accounts for approximately 80% of collagens 
and type III collagen constitutes 10% of collagens in the dermis (23, 24). With wound 
closure, a gradual turnover of collagen occurs as type III collagen undergoes degradation and 
type I collagen synthesis increases. Type I collagen synthesis coincides with increased wound 
breaking strength(25). 
1.6 Factors affecting wound healing 
Several clinical conditions and factors are known to impair wound healing.  Some of the 
factors are: 
Infection:  
The number of microorganisms and their degree of pathogenicity determine the establishment 
of infection. Infection delays wound healing. Hospital-acquired infections are associated with 
virulent organisms and are a great cause for concern. Misuse or overuse of antibiotics leads to 
resistance of these and to the emergence of new bacterial strain (26). 
The mere presence of bacteria does not always indicate that a wound is infected. Many 
patients who have chronic wounds which are colonized by bacteria progress to complete 
healing without any setbacks(27). Critical colonization refers to the point where a wound is 
unable to maintain a balance between the number of microbes and the defense systems 
available. At the point of critical colonization, a wound may not show the multiple classical 
signs of infection but may cease to heal and become indolent (28).  
The infecting microorganisms may belong to aerobic as well as anaerobic group. Most 
commonly isolated aerobic microorganisms include: S. aureus, Coagulase-negative 
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staphylococci, Enterococci, Escherichia coli, Pseudomonas aeruginosa, Klebsieila 
pneumoniae, Enterobacter species, Proteus mirabilis, Candida with 80% Candida albicans 
(29). S. aureus from gram positive and P. aeruginosa from gram negative are the most 
common pathogens which infect the skin(30). 
Anaerobic bacteria may also involve as a result of chronic wound due to abscess formation 
and the resulted low tissue oxygen level. Some of them are Prevotella, Bacteroides, 
Peptostreptococcus and Porphyromonas(11). 
Oxygenation  
Oxygen is important for cell metabolism, especially energy production by means of ATP, and 
is critical for nearly all wound healing processes. In healing tissue, sufficient oxygenation is 
particularly relevant because of the increased energy demand for reparative processes such as 
cell proliferation, bacterial defence and collagen synthesis (31). Wound healing is impaired 
under hypoxia and topical oxygen therapy is known to promote healing (22).   
Nutrition:  
 Protein, Vitamins C, B and A, Zinc, Iron and Copper are essential for wound healing. Protein 
is required for healing tissues and. An adequate energy intake is essential to prevent dietary 
and tissue protein being used as a source of energy rather than for wound healing. Vitamin A 
promotes epithelialization and granulation of healing wounds. Zinc, Vitamin E and C are 
necessary for collagen formation, epithelialization and cell proliferation, proper immune 
function. Vitamin C and E are known antioxidants.  Copper is necessary for collagen 
formation and essential for red blood cells formation (26, 32, 33). 
Drug Therapies: 
Many medications, such as those which interfere with clot formation or platelet function, or 
inflammatory responses and cell proliferation have the capacity to affect wound healing. 
Cytotoxic drugs interfere with cell proliferation and may cause neutropenia, making the 
patient more susceptible to wound infection. Long-term use of corticosteroids may suppress 
fibroblast and collagen synthesis. They also impede wound healing through reduction of 
neutrophils and inhibition of leukocyte and tissue macrophage function. Non-steroidal anti-
inflammatory drugs suppress the normal inflammatory response and may affect healing by 
causing vasoconstriction (26, 31, 32).  
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Co morbidities: diabetes, obesity 
Poorly controlled diabetes results in cellular dysfunction that impedes all phases of wound 
healing. During hemostasis, there is decreased platelet derived growth factor receptor 
expression on epithelial and endothelial cells, resulting in delayed transition to inflammation. 
An increase in the number of wound activated macrophages causes increased and prolonged 
expression of inflammatory cytokines, thereby prolonging the inflammatory phase. Peripheral 
vascular disease is a common complication of diabetes and can lead to peripheral ischemia. 
Decreased blood flow to an area of ulceration due to diabetes or obesity results in reduced 
oxygenation, nutrition and healing rates (32). 
Formation of free radicals 
 The enzymes and ROS produced by neutrophils and other leukocytes damage cells and 
prevent cell proliferation and wound closure by damaging DNA, lipids, proteins, enzyme, 
including free radical scavenger enzymes, the ECM and cytokines that speed healing. 
Neutrophils remain in chronic wounds for longer than they do in acute wounds. Agents that 
demonstrate significant antioxidant activity may, therefore, preserve viable tissue and 
facilitate wound healing(34). 
Smoking and alcohol abuse  
Nicotine reduces cutaneous blood flow by vasoconstriction, stimulates release of proteases 
that may accelerate tissue destruction, suppresses the immune response and leads to an 
increased risk of infection. In the proliferative phase, smoking decreases fibroblast migration, 
wound contraction, epithelial regeneration, and extracellular production(32, 35). In alcohol 
abusers, there is a decrease in the inflammatory and immune responses to injury that result in 
both delayed healing and increased risk of infection, decrease fibroblast migration, and 
angiogenesis during the proliferative phase, and decrease type I collagen production with 
concurrent increase in protease activity during the remodeling phase resulting in weaker 
extracellular matrix(32). 
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1.5 Models for wound healing study 
There are different in vitro and in vivo models to study wound healing activity of agents 
including, medicinal plants (36).  
1.5.1 In vitro Studies 
 In vitro assays are useful in wound healing research. By using in vitro assay methods, it is 
possible to screen multiple agents or samples simultaneously. The limitation for the use of in-
vitro assays is that they require well-furnished laboratory settings (36).  
Chick chorioallantoic membrane Assay  
This model is designed to evaluate the activity of wound healing agents on angiogenesis. 
Angiogenesis plays an important role in wound healing and newly formed blood vessels 
comprise 60% of the repair tissue. Anaerobic wound is difficult to heal faster than aerobic 
wound can. The increased vessel growth can facilitate both the extent and direction of 
fibroplasia.  Improved angiogenesis, therefore, would be contributing significantly to wound 
healing activity of the test drug (37).  
Fibroblast Assay  
In this assay, the proliferation of fibroblasts can be assessed by determination of the total 
protein of viable cells present in culture. Fibroblasts secrete collagens and subsequently 
increase the tensile strength of wound to form a strong scar tissue. Their main importance is 
in the secretion of various growth factors, such as PDGF and TGF-B that stimulate 
proliferation/ differentiation/migration of other cells involved in the wound healing process. 
Fibroblasts also form keratinocytes. This means that a high proliferative keratinocyte cell 
layer is spreading from the edges towards the wound area, finally leading to a closed cover-
layer (38). 
Collagen Assay  
Different collagen types (I–V) can be determined. The amount of collagen protein is simply a 
reflection of how strong and good quality the repaired tissue is (36, 39).  
Collagenase and Elastase Inhibition Assay  
Extracellular matrix is composed of proteoglycans and matrix metalloproteins such as 
collagen and elastin. Collagen is the major structural protein provides supportive framework 
to the cell, elastin maintains the skin’s elasticity and hyaluronic acid keeps the moist. All 
three components help the wound healing process. Therefore, inhibition of the enzymes that 
break down these ECM components could contribute wound healing (40). 
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MPO assay  
Myeloperoxidase is an enzyme that is found predominantly in the granules of neutrophils and 
can be used as a quantitative index of inflammatory infiltration in the wound (39).  
1.5.2. In Vivo Studies 
 The small mammals have emerged as the model of choice for researchers, which are 
beneficial for multiple reasons. They are inexpensive; require less space, food, water & easy 
to maintain. Additionally, they often have multiple offspring, which develop quickly allowing 
experiments to proceed through multiple generations (36).  
 Excision Wound Model  
This model is used for the study of rate of contraction of wound and period of epithelization. 
Excision wounds are inflicted on the dorsal thoracic region 1–1.5 cm away from the vertebral 
column on either side and 5 cm away from the ear. The circular skin from the predetermined 
area on the depilated back of the animal is excised to its full thickness to obtain a wound area 
of about 200-500 mm2 diameter and 2 mm depth. In this method, collagen estimation, 
percentage wound contraction, and period of epithelialization parameters are studied (41, 42). 
Incision Wound Model  
After wound area preparation with 70% alcohol, longitudinal 4–6 cm in length paravertebral 
incision is made through the skin and cutaneous muscles. The parted skin is stitched with 
interrupted sutures, 0.5–1.0 cm apart using black braided silk surgical thread (no.000) and a 
curved needle (no. 11). The continuous threads on both wound edges are tightened for good 
closure of the wound. The sutures were removed on 8th day, and the skin breaking strength of 
the healed wound is measured on 8th–10th day. The tensile strengths, biochemical and 
histological study of the wound are carried out (43, 44).  
Dead Space Wound Model  
In this model, the physical and mechanical changes in the granuloma tissue are studied. The 
subcutaneous dead space wounds are inflicted one on either side of axilla and groin on the 
ventral surface of each animal, by making a pouch through a small nick in the skin. The 
cylindrical grass piths (2.5 × 0.3 cm) or sterile cotton pellets (5–10 mg each) are introduced 
into the pouch. Granulation tissue forms on the dead space wound surrounding the implanted 
pellets/piths is harvested by careful dissection on the 10th post wounding day under light 
ether anaesthesia. After noting the wet weight of the piece of granuloma excised, it is dried in 
an oven at 60◦C for 12–24 h to obtain a constant dry weight expressed as mg/100 g body 
weight (45). 
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Burn Wound Model  
These wounds are also measured for the contraction. A special metal plate 2×2 cm with 
holder is heated to 60◦C and applied to the dorsal area of the animals for 30 seconds to induce 
partial thickness burn wound. Second-degree burns wound can be made by placing the 90◦C 
hot plate on the selected dorsal area of the animal for 10 secs. While for full thickness burn 
wound, the metal plate is heated to 100◦C and applied to the dorsal area for 30 secs or a 
partial thickness burns wounds can also be inflicted upon animals starved overnight and 
under mild anaesthesia, by pouring hot molten wax at 80◦C into a metal cylinder with 100–
300mm2 circular opening, placed on the back of the animal. Like excision wound, percentage 
wound contraction, hydroxyproline content and epithelialisation time can be studied (36, 46).  
1.6 Management of wounds 
1.6.1 Antimicrobial agents 
The aim of wound care is to promote wound healing in the shortest time possible, with 
minimal pain, discomfort, and scarring to the patient and must occur in a physiologic 
environment conducive to repair and regeneration (47). The term “antimicrobial agents” 
comprises disinfectants, antiseptics, and antibiotics. Strategies to rid of microbes can include 
the use of expensive silver-containing dressings, the application of topical antibiotics or 
antiseptics, or even the routine use of long-term systemic antibiotics  (30).  
Various topical antimicrobial agents have been reported to have role in wound healing.  
Topical antibiotics are of low risk of systemic side effects, have a higher concentration in the 
affected area, low quantity of drug usage, and none interference with intestinal flora. The 
goal of topical antimicrobial therapy in wound care is to control microbial colonization and 
subsequent proliferation thus promoting the healing of the wounds. Topical antimicrobials are 
available in the form of lotions, creams, ointments, powders, gels, foam and sprays. Topical 
preparations that may be helpful include amikacin (in gel or cream), bacitracin, 
chloramphenicol, clindamycin (cream, lotion, and foam), gentamicin (available in form of 
ointment or cream), nitrofurazone (available as a 0.2% cream, solution, or soluble dressing) 
and polymyxin B (48). Povidone iodine is available commercially in several formulations 
(solution, cream, ointment, dry spray or dressings). Silver has a long history as an 
antimicrobial agent especially in the treatment of burns. In clean wounds in pigs, silver 
sulphadiazine increased the rate of epithelialization by 28%, indicating a beneficial effect in 
wounds additional to antimicrobial activity(49). 
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1.6.2 Traditional medicinal plants 
In addition to antimicrobial agents, medicinal plants have been long used for treatment of 
various ailments of skin and dermatological disorders especially cuts, wounds and burns(50). 
Between 70% and 95% of citizens in the majority of developing countries use traditional 
medicine as primary health care to address their health-care needs and concerns(51). Ethiopia is 
also endowed with more than 800 species of plants that are used in the traditional health care 
system to treat various disorders including skin disorders (52). Thus, traditional medicine still 
remains the main resource for a large majority of the people in Ethiopia for treating health 
problems.  
1.7 Literature Review 
Research on wound healing agents is one of the developing areas in modern biomedical 
sciences and there are so many studies on wound healing that are conducted on rodents by 
using the different wound healing models. Many traditional practitioners across the world 
have valuable information of many plants for treating wounds and burns. The presence of life 
sustaining constituents in plants has urged scientists to examine these plants with a view to 
determine potential wound healing properties. Thus, traditional forms of medicine practiced 
for centuries in Africa and Asia are being scientifically investigated for their potential in the 
treatment of wound related disorders(53, 54). 
Different species within the Brassica genus were studied on their wound healing activity. The 
study on comparison of different extracts (using petroleum ether, chloroform, ethanol and 
water) leaf of Brassica juncea Linn on wound healing activity in excision wound model 
showed that all the extracts were found to be extremely statistical significant and comparable 
with positive control. Further wound healing activity was found to be better than standard 
treated group (Povidone-Iodine Ointment (5% w/w)) which may be attributed to the faster 
action of the active phytochemical constituent. Moreover, among different extracts, the 
aqueous extracts showed 94.94% maximum percentage of healing compared to control(55). 
A similar study on ointment of Brassica oleracea var. capitata showed maturation of the 
extracellular matrix in skin wounds of wistar rats as evidenced by significant levels of total 
collagen and glycosaminoglycans found to occur starting from 8th day (p< 0.05) compared to 
negative control. Collagen, the major protein of extracellular matrix, is the component which 
gives strength, support and integrity to the wound matrix (56). 
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The hydro alcoholic extract and the different solvent fractions(chloroform, acetone and 
methanol) obtained from the leaves of A. abyssinicus were evaluated for their wound healing 
and anti-inflammatory activities in mice and were reported that  the methanol fraction 
levigated in simple ointment at concentrations of 5% and 10% was found to be the most 
active in the excision wound model. Also, the same fraction exhibited good healing effect in 
incision model in a dose dependent manner(57).  
Another longitudinal study on evaluation of wound healing activity of rhizomes of Rumex 
abyssinicus J. in mice on different wound models revealed that treatment of wound with 
ointment containing 5% and 10% (w/w) hydro alcoholic extract (using 80% methanol) 
exhibited significantly increased wound contraction rate, shorter epithelization time, and 
higher skin breaking strength in the two experimental models viz. excision and incision 
models as compared to control. 10% (w/w) hydro alcoholic extract ointment showed better 
wound healing property than the 5% (w/w) ointment and its effect was comparable to that of 
the reference standard (nitrofurazone)(58).  
The finding of in vitro antibacterial activities of Broccoli (Brassica oleraceaL.varitalica) 
against six food borne bacteria viz., Bacillus cereus, Bacillus subtilis, Staphylococcus aureus, 
Escherichia coli, Salmonella typhimurium and Shigella flexneri showed that B. subtilis (15.4 
mm) and Bacillus cereus (16.3 mm) were found to be the most sensitive organisms. However, 
Staphylococcus aureus and Escherichia coli were found to be resistant (59). On the other 
hand, the antimicrobial activities of 70% ethanolic seed extracts of Brassica nigra were 
evaluated against different bacterial strains (E.coli, Pseudomonas aeruginosa, Candida 
albicans) by agar well diffusion method & MIC determination by broth dilution method. The 
extract showed a broad spectrum of antimicrobial activities by inhibiting the growth of 
respective microorganism in Agar well diffusion assay (60).  
A review on health promoting bioactive phytochemicals from Brassica genus viz B. nigra, B. 
juncea, B. oleracea and B. rapa explored the presence of phenols and flavonoids in high 
amount which were reported for their free radical scavenging properties and anti-
inflammatory activities as most important actions. Particularly, Sinapic acid, an isolated 
phenolic compound and kampferol and quercetin, the flavonoids isolated from brassica 
vegetables were reported to have anti-oxidant activity (61). 
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In addition to this, Sinigrin is a major glucosinolate, associated with the family of glucosides 
present in the Brassicaceae family, such as the seeds of black mustard (Brassica nigra), 
Indian mustard (Brassica  juncea) and Brassica oleracea L.var. A number of studies have 
been performed on the therapeutic activities of sinigrin and revealed its anticancer, anti-
inflammatory, antibacterial, antifungal, antioxidant, and wound healing effects (62). 
A review on studies of phyto-extracts in wound healing of more than 500 plant species 
demonstrated that the main effects of the active constituents of the plant extracts towards 
wound healing are 1) Phyto-chemical constituents contributing to antimicrobial activity 2) 
Phyto-chemical constituents working as antioxidants and as free radical scavengers  3) Active 
components having enhanced mitogenic activity (contributing to increased cell proliferation), 
angiogenesis, enhanced collagen production and increased DNA synthesis 4) phyto-chemical 
constituents having anti-inflammatory properties. Based on this information, among the 
soluble compounds in the plant extracts, the flavonoids, polyphenols, tannins, saponins, 
terpinoids, and sterols have been found to possess considerable anti-microbial, anti-oxidant 
and free radical scavenging activities and therefore facilitated wound healing. Some plants 
that are reported to have wound healing and related activities include: Brassica Juncea, 
Brassica oleracea, and Brassica nigra from brassica genera, Allamanda cathartica, Artemisia 
absinthium, Coronopusdidymus, Cuminumcyminum, Flaveriatrinervia, Heliotropiumindicum 
and others (13, 63, 64).  
1.8 The Experimental plant 
Brassica carinata A. Braun – Ethiopian mustard also called ‘Gomenzer’ in Amharic is an 
erect, annual herb growing from 30 to 200 cm tall (65). Brassica carinata A. Braun is amphi-
diploid species that belong to the family Brassicaceae. It originated through inter specific 
hybridization between Brassica nigra and Brassica oleracea in the highlands of Ethiopia and 
adjoining regions of East African and Mediterranean coast (66). 
Traditionally, B. carinata seeds are used to grease clay pan used for baking traditional 
Ethiopian bread “enjera”, to cure certain ailments or stomach upsets and to prepare some 
beverages. The leaves of young plants are good sources of vegetable relish (67).  Brassica 
carinata seed is one of the traditional medicinal plant species used to traditionally manage 
wound. It was also mentioned that B.carinata is used in the management of common cold 
(68). 
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Previous report indicates Brassica carinata A. Braun leaf was tested in the in vitro HL60 
(human promyelocytic leukaemia cell line) and in vivo Drosophila melanogaster systems to 
determine the anti-mutagenic and anti-tumor properties.  In vivo antigenotoxicity assays 
showed that this plant behaves as a desmutagen by reducing the apparition of mutations in 
comparison with negative control. B. carinata did not exert any DNA damage in the mwh/flr 
eukaryotic system of D. melanogaster. In vitro HL60 assays showed B. carinata showed a 
dose-response curve with a high tumoricide activity (IC50 value of 0.28 mg/ml ) (69).  
 
Figure 1: photograph of Brassica carinata A Braun (Brassicaceae)  
1.9 Rationale of the study 
Despite there is no much data on the current status of wound problem in developing 
countries, large population in developing countries experience acute and chronic wound due 
to different reasons such as trauma, disease epidemics etc.  In one report the prevalence of 
chronic wounds in sub-Saharan Africa was 4.5 per 1000 population, whereas that of acute 
wounds was 10.5 per 1,000 populations (11). Patients incur numerous direct and indirect 
medical costs during wound treatment. Above all psychosocial outcomes and physical health 
outcomes comprise the majority costs of trauma in sub-Saharan Africa. Different health 
impacts as a result of wound complication include disability that results in lost wages, 
decreased productivity and a diminished quality of life. Cellulites, abscess formation, 
osteomyelitis, gangrene and even sepsis may occur as a result of an infected wound. 
Furthermore, chronic wounds have the potential for malignant transformation(12).  
14 
 
The current management of wound, acute or chronic, and skin and soft tissue infections 
largely focuses on the use of antimicrobial agents (70).  In fact, antimicrobial agents may 
have role to promote wound healing by prevention of infection in the wound or by treatment 
of infected wound. But almost all are suffering from antimicrobial resistance or systemic 
adverse effects. Therefore, there is a need to discover a lead compound having potent anti-
oxidant, anti-inflammatory, enhanced mitogenic activities apart from antimicrobial activity 
and allow using it for long time without fear of resistance or systemic side effects with the 
aim to promote wound healing in the shortest time possible, with minimal pain, discomfort, 
and scarring to the patient.  
In developing countries, majority of people almost exclusively use traditional medicines in 
treating all sorts of diseases, including wound. In this regard, an ethno botanical study of 
medicinal plants in selected Horro gudurru woredas, Western Ethiopia showed that B. 
carinata as one of the many plant species used to traditionally manage wound(68).  
Moreover, different species within the Brassica genus were studied on their wound healing 
activity (55, 71). Also, different studies on species of brassica genus, such as Brassica nigra, 
Brassica juncea and Brassica oleracea confirmed the presence of different phytochemicals 
that have been demonstrated to have anti-inflammatory, antioxidant and wound healing 
properties. High content of poly phenols and flavonoids in brassica species contribute to their 
antioxidant property, anti-inflammatory and therefore wound healing activity (55, 59, 60, 63, 
71).  Hence, this study evaluated the wound healing activities of the crude as well as solvent 
fractions of seeds of this plant and justified its acclaimed use by the traditional practitioners. 
Thus, the finding of this study might serve as source for the development of new drugs.  
Furthermore, it might serve as baseline information for scientific community to further 
investigate the plant Brassica carinata with the aim to identify the specific agent responsible 
for the wound healing effects of the extract. 
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2. OBJECTIVE 
2.1 General Objective 
The aim of this study was to evaluate the wound healing activities of the 80% methanol crude 
extract and solvent fractions of B. carinata seed in mice. 
2.2 Specific objectives 
The specific objectives of the study were including: 
 To evaluate acute dermal toxicity of the 80% methanol seed extract in rats 
 To evaluate the wound healing effect of the 80% methanol seed extract by using excision 
and incision wound models in mice 
 To evaluate wound healing activity of solvent fractions in excision wound model in mice 
 To evaluate antibacterial activity of 80% methanol crude extract on selected pathogens 
 To carryout preliminary phytochemical screening of crude extract and solvent fractions 
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3. MATERIALS AND METHODS 
3.1. Chemicals, Reagents and Equipments  
Ketamine hydrochloride (Neon laboratories, India,) , ethyl acetate (AppliChem Gmbh 
Ottoweg 4 D64291Darmstadt, Germany), methanol (Carlo Erba Reagents, Italy), chloroform 
(Nice chemicals Pvt. Ltd, India,), distilled water, Tween 80 (2%), 70 % denatured alcohol 
(Acurex chemical manufacturing P.L.C), diethyl ether (Blulux Lboratories  Pvt.  Ltd, India), 
0.2% nitrofurazone (Galentic pharma, India  Pvt Ltd), wool fat (Blulux Lboratories  Pvt. Ltd, 
India), hard paraffin (Blulux Lboratories Pvt.  Ltd, India), white soft paraffin (Blulux Lboratories  
Pvt.  Ltd, India), cetostearyl alcohol (Avishkar International Pvt. Ltd), Mayer’s reagent, K3Fe 
(CN)6, FeCl3, Lead acetate solution, Sodium chloride, Reference antimicrobial susceptibility 
test discs of ampicillin (Himedia Laboratories Pvt. Ltd, India), cefoxitin (Himedia 
Laboratories Pvt. Ltd, India), ciprofloxacin (Himedia Laboratories Pvt. Ltd, India ) was used. 
In addition, other agents like a readymade 0.5 McFarland standard (Remel, Lenexa Kansas 
66215, USA) was used during the study. The bacteriological media that was used in the study 
includes Muller Hinton agar (MHA) (Himedia Laboratories Pvt. Ltd, India), blood agar. All 
chemicals and reagents used were of laboratory grade. Other materials included surgical 
blade, suturing silk, allice ferceps, graph paper, shaver and permanent marker. 
3.2 Plant material 
Matured seed pods of B carinata were collected from one of the local farming lands of Adet 
district, West Gojjam, North Western Ethiopia.  The plant material was identified and 
authenticated by a botanist from Biology Department, College of Computational and Natural 
Science, University of Gondar and was given voucher number BK001. 
3.3 Experimental animals 
Healthy adult Swiss albino mice of either sex (25-30 g, and 6-8 weeks of age) and female 
adult albino rats (200-300 g, aged 8-12 weeks) were obtained from the animal house of the 
Department of Pharmacology, University of Gondar. The animals were housed in cages under 
standard environmental conditions in animal house of department of pharmacology (12 h 
light and dark cycles). They were maintained on standard pellet diet and water ad libitum 
throughout the experiment. All the experiments were conducted in accordance with the 
internationally accepted laboratory animal use, care and guideline (72). The animals were 
acclimatized to laboratory condition for at least 5 days prior to the experiments. 
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3.4 Extraction  
First, the seeds were grounded to coarse powder using wooden mortar and pistil. Crude 
extraction was carried out by maceration protocol. Briefly, 2000 grams of the coarse powder 
was weighed and macerated in Erlenmeyer flasks with 6250 ml (5000 ml methanol and 1250 
ml distilled water) of 80% methanol in distilled water for a period of 3 days with occasional 
shaking at room temperature. Then, the extract was initially filtered by gauze (muslin) and re-
filtered using Whatman No 1 filter paper. The marc was re-macerated for the second and 
third times with 80% methanol, for a total of 6 days. After filtration, the three extracted 
solutions were combined and concentrated in hot air oven adjusted to a temperature of 38 oc 
to remove methanol. After it was dried in the oven, it was then put into a desiccator to 
completely remove the aqueous content and further maintain dryness. After complete drying, 
the percentage yield of the crude extract was determined.  Finally, the dried crude extract was 
packed in a closed vessel and stored in deep freezer until fractionation took place. 
3.5 Preparation of solvent fractions 
 First, 60 grams of the crude extract was weighed and dissolved in 200 ml of distilled water 
and 2% tween 80. Then the suspension was poured into a separatory funnel into which 150 
ml of chloroform was added and shaken gently. Because the density of chloroform is greater 
than water and also immiscible, it forms two phase with the bottom for chloroform fraction 
and the top for aqueous phase. Chloroform was added three times and filtered to obtain the 
chloroform fraction. Likewise, the marc of chloroform fraction was shaken by adding 150 ml 
of ethyl acetate each time for 3 times and filtered to obtain the ethyl acetate fraction. The 
density of ethyl acetate is less than water and so formed the top phase. The final marc left 
after was taken as aqueous fraction. Then, the chloroform fraction and ethyl acetate fraction 
were concentrated in hot air oven adjusted to a temperature of 38 oc to remove the solvents.  
Then it was placed in a desiccator. The percentage yield of the aqueous fraction, ethyl acetate 
fraction, and chloroform fraction were calculated. 
3.6 Formulation of ointments of extracts 
Fusion method was employed in the preparation of non-medicated ointment base. The crude 
extract and solvent fractions were formulated using simple ointment base at 5% and 10% 
concentrations. Levigation (spatulation) method was employed in ointment preparations of 
extracts. Simple ointment was used as a base for the ethyl acetate, chloroform and water 
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extracts. Ointment formulations were prepared in accordance with British Pharmacopoeia 
(73). 
3.7 Preliminary phytochemical analysis 
The 80% methanol crude extract of the plant was screened for the presence of secondary 
metabolites(74, 75). Briefly, to 0.5 ml of the extract, a drop or two of Mayer’s regent was 
added and the formation of white or creamy precipitate indicated the presence of alkaloids. 
Formation of brown ring at interface by the addition of 2 ml of glacial acetic acid followed by 
few drops of ferric chloride solution and 1 ml of conc. sulphuric acid to the extracts revealed 
the presence of glycosides. Adding few drops of 2% ferric chloride to the extract and 
development of dark green color indicated the presence of phenols. Existence of froth 
formation during vigorous shaking indicated saponins. Addition of 2 ml of chloroform and 3 
ml of conc. sulphuric acid to the extract and formation of reddish brown layer at the junction 
of two solutions confirmed terpenoids. To 2 ml of the extract solution, three to five drops of 
2% lead acetate solution was added and formation of orange/ yellow color indicated 
flavonoids. A red color produced in the lower chloroform layer when 2 ml of extract was 
dissolved in 2 ml of chloroform and 2 ml concentrated H2SO4 added showed steroids. 
Appearance of brownish green or blue black coloration after adding 0.1% ferric chloride to 
the extract revealed tannins.  
3.8 Acute dermal toxicity: fixed dose procedure 
The test was performed according to the OECD draft guideline number 434(76).  For dermal 
toxicity, a total of ten albino female rats of age between 8 and 12 weeks old were used since 
female rats are more sensitive to dermal toxicity than mice.  They were divided into two 
groups of five animals each for a treatment and a control groups. Animals that show normal 
skin texture were housed individually in a group cage and acclimatized to the laboratory 
condition for five days prior to the test. Following acclimation, around 10 % of the body 
surface area fur was shaved 24 h before the study from the dorsal area of the trunk of the test 
animals. A limit test dose of 2000 mg/kg of the 10 % formulation of the crude extract was 
used. Initially, sighting study was conducted with one animal for the first 24 hrs. The 
remaining four rats were tested on the following day having obtained the information about 
safety in the sighting study. Observations for any signs of adverse skin reactions, 
inflammation or edema were made for 24 hrs with special attention within the first 4 hrs. The 
animals were also observed for development of any adverse skin reactions daily for 14 days. 
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3.9 Wound healing activity  
3.9.1 Excision model 
In this model, both the crude extract and solvent fractions were evaluated. Four groups of 
mice containing six in each were used for excision model. On wounding day, animals were 
anesthetized using subcutaneous injection of ketamine (1 ml/kg equivalent to 50mg/kg) and 
the back hair of the animals was shaved by shaver. Approximately about 300 mm2 circular 
area was marked and the full thickness of the marked area was carefully excised by using 
sharp sterilized surgical blades. The mice were left undressed to the open environment (42). 
After 24 h of wound creation, the ointments were applied gently once daily to cover the 
wound area until complete healing was achieved. Animals in Group I were treated with 
nitrofurazone (0.2%) ointment. Group II and III will receive 10% (w/w) and 5% (w/w) 
extract ointments, respectively, and the animals in group IV were treated with simple 
ointment. Then rate of wound contraction and epithelization time were monitored.  
Epithelialization time:  measured the number of days after wounding required for the scabs 
to fall off leaving no raw wound behind (58).  
Wound contraction: Wound contraction rate was monitored by measuring the wounds every 
other day beginning from the 1st day (original wound). So, the wound healing progress was 
evaluated by measuring wound areas on days 2, 4, 6, 8, 10, 12, 14 and 16 for all the groups 
using a transparency sheet and a permanent marker. Then, the traced area for each mouse was 
calculated by using scaled paper (graph paper), each small square representing 1 mm2. 
Wound contraction was calculated as percent reduction in wound area. The following 
formula was employed to calculate the percentage of wound contraction (57, 58). 
% contraction of Wound area=        initial wound area- specific day wound area * 100 
                                                                      Initial wound area       
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    Figure 2:    Day 0 wound creation  
3.9.2 Incision model  
In this model, the crude extract was evaluated for wound healing activity. The mice were 
anesthetized in the same manner as described for excision wound model. The paravertebral 
fur was carefully shaved. A site of 3 cm length parallel to the vertebral column of the animal 
was marked with permanent marker and incised with sharp surgical blade. Then, the parted 
skin was closed with interrupted suture within 1cm, equidistant position (43, 57, 58). Full 
aseptic measures will not be taken and no local or  systemic antimicrobials were used 
throughout the experiment (77).  On the first day, the animals was divided into four groups (6 
per group) to start ointment application. Two groups were control groups (negative and 
positive controls-group I and II) and the other two were test groups (with 5 & 10% w/w crude 
extract ointment i.e. group III and IV). The ointments were applied on daily bases to each 
mouse till the end of the test period. On the 8th day of post wounding the sutures was 
removed and the application of the ointments was continued till the 9th day. On the 10th day 
the breaking or tensile strength of the wound was measured for each mouse after the mice 
were anesthetized. 
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Measuring breaking strength of wound:  
The breaking strength of the wound on each animal was measured by using constant water 
flow method (78). In this method, the animals were first anesthetized using diethyl ether and 
positioned on a table between two metal stands. To both stands, allice forceps of equal size 
was suspended with strings, one of which passed on a small wheel with the stands. One of the 
forceps served as a support and the other forceps holded a plastic of volume 1000 ml (plastic 
bottle). Then, both forceps were allowed to grip the edges of the wound 3 mm away in both 
sides. After this, constant water flow was allowed to enter to the plastic bottle which was 
suspended with the string that passed on the wheel until the wound opened up (broken). The 
flowing water was stopped immediately as the wound breaks in each mouse. Then the 
volume of the water in the plastic bottle was measured by using a measuring cylinder which 
was taken as the wound breaking strength for the individual mouse (in grams since the 
density of water 1 gm/ml). 
Percent tensile strength was calculated by using this formula 
Percent tensile strength (TS) of extract =      TS extract – TS simple ointment * 100 
                                                                                  TS simple ointment 
                                                             
 Figure 3: Water flow technique: measurement of tensile strength  
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3.10 In vitro antibacterial activity 
3.10.1 Media and bacterial inoculums preparation 
Standard bacterial strains include E. coli ATCC 2592), P. aeruginosa ATCC 2785, S. aureus 
ATCC 25923, k. pneumonia ATCC 1705, and S. pyogen ATCC 19615 were obtained from 
Microbiology Department of Gondar University. The bacteria were selected by considering 
the likely bacterial strains that can cause skin and soft tissue infections or wound infections. 
Then, Muller Hilton agar and 5% blood agar (for fastidous streptococcus pyogens that 
requires enriched media) was prepared following the manufacturer’s protocol. Bacterial 
suspensions were also prepared and standardized to a density of 108 CFU/ml of 0.5 
McFarland standards. The turbidity of each bacterium was prepared and standardized by 
following the guideline of Clinical and Laboratory Standard Institute (CLSI, 2014).  
Commercial antibiotic discs of ampicillin 10 μg/disc (for streptococcus pyogens), cefoxitin 
30 μg/disc (for E. coli and S. aureus species) and ciprofloxacin 5 μg/disc (for P. aeruginosa 
and k. pneumoniae ) were used as a positive control (79). 
3.10.2 Agar well diffusion antibacterial activity assay 
The crude extract was subjected to this assay. According to Clinical and Laboratory Standard 
Institute, 2014 MHA was prepared by following manufacturer’s protocol and dispensed to 
petridishes in a biological safety cabinet. Then, it was allowed to incubate at 37⁰C for 24 h 
for sterility testing.  After sterility was assured, aseptically 3-5 colonies of the respective 
bacterial inoculums were streaked on the sterile MHA plates/petridish by a sterile wireloop 
and incubated at 37⁰C for 24 hr. On each plate, five equidistant wells were made with a 6 mm 
diameter sterilized cork borer and then filled with the antibiotic disc, distilled water, and 100 
μl extract of 125 mg/ml, 250mg/ml and 500mg/ml concentrations on each separate wells. The 
plates were then incubated at 37⁰C for 24 hr. Commercial antibiotic discs as positive controls 
and distilled water as negative control were used. Finally, diameters of zones of inhibition 
were measured(79). Initially pilot study was performed on S. aureus and p.aurignosa at 125 
mg/ml, 250mg/ml and 500mg/ml concentrations of the extract. Based on the findings, larger 
concentrations of 850 and 750 mg/ml were taken and assayed against all selected species. 
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3.11 Ethical considerations  
All the experiments were conducted in accordance with the internationally accepted 
laboratory animal use, care and guideline (72). Ethical approval was obtained from Research 
and Ethical Review Board of university of Gondar before the initiation of the study.  
3.12 Data analysis 
Data were entered, cleaned, coded, checked and analyzed by using SPSS version 20 software. 
Statistical significance was carried out by employing one way ANOVA followed by Tukey 
post Hoc test, where P<0.05 was considered as statistically significant. The experimental 
results were expressed as mean ±standard error of the mean (SEM).  
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4. RESULTS  
4.1 Crude extract and solvent fractions 
The percentage yield value of the crude extract was determined and found to be 5.75%. The 
percentage yield values of chloroform, ethyl acetate and aqueous fractions were 10.83 %, 15 
%, and 74.17% respectively.  
4.2 Preliminary phytochemical screening 
Preliminary phytochemical analysis of the 80 % methanol of Brassica carinata seed and its 
solvent fractions showed positive results for polyphenols, alkaloids, flavonoids, saponins, 
tannins, glycosides and steroids. Both the crude extract and solvent fractions were negative 
for terpinoids (Table 1). 
Table 1: Preliminary phytochemical analysis of Brassica Carinata A Braun extracts  
Secondary 
metabolites  
Reagents/ 
chemicals  
Crude 
extract 
Chloroform 
Fractions  
Ethyl 
acetate  
Fractions  
Aqueous 
fractions 
Alkaloid  Mayer’s reagent + + + + 
Flavonoids  lead acetate + + + + 
Phenols  1%  FeCl3  + + + + 
Terpinoids  H2SO4+ chloroform - - - - 
Saponins  Vigorous shaking + - + + 
Tannins  0.1% ferric chloride + + + + 
Steroids  H2SO4+ chloroform + + + + 
Glycosides  glacial acetic acid + + + + 
     (+) presence, (-) absence 
  
25 
 
4.3 Acute dermal toxicity 
The 10% w/w ointment of crude extract was found to be safe. There were no any signs of 
skin reactions, inflammation or edema within 24 hrs of topical application with special 
attention was given for the first 4 hrs. The mice were also monitored for 14 days and neither 
mortality nor any signs of skin toxicity were observed. 
4.4 Wound healing activity of crude extracts  
4.4.1Excision wound  
A. Wound contraction  
Topical application of 80% methanol extracts of B. carinata seed showed effect on wound 
healing in mice. The progress of wound contraction induced by treatment of 5% (w/w) and 
10% (w/w) of 80% methanol seed extract of B. carinata, negative control and nitrofurazone 
0.2% (w/w) ointment preparations are shown in Table 2. Contraction of the excision wound 
was promoted till day 16 in extract and standard control treated groups. 
The 10% (w/w) methanol extract exhibited significant (p< 0.001) wound contraction from 6th 
to 16th days of treatment as compared to the negative control. In comparison with the 5% 
(w/w) extract, it has also exhibited significant wound contraction activity on 6th (p = 0.003), 
8th (p = 0.025) and 10th (p = 0.021) days of treatment. However, the difference in wound 
contraction activity between 10% (w/w) and 5% (w/w) extracts before the 6th and after the 
10th days of treatment was not significant (Table 2). The 10% (w/w) extract treatment 
demonstrated the higher percentage of wound closure, 96.6%, 99.1% and 100% at 12th, 14th 
and 16th days of treatment, respectively (Figure 3) while the percent wound closures induced 
by the positive control were 92.2% (day 12), 98.4 % (day 14) and 100% (day 16). 
The 5% (w/w) extract showed significant (p<0.01) wound contraction from 8th day onwards 
when compared with negative control. Even though there was no significant difference, the 
positive control showed better activity than 5% w/w extracts. The percentage wound closure 
of 5% w/w extract on the 12
th
, 14
th 
and 16
th 
days was 87.6, 96.0, and 99.5%, respectively.  
Complete wound closure in 10% (w/w) extract and positive control was observed at 16th days 
while it took about 18 days in the 5% (w/w) extract, (Figure 2). 
  
26 
 
Table 2: Effects of the 80% methanol extracts of the seed of Brassica carinata on wound  
Wound area (mm
2
) post-wounding days  
 
                0                2             4              6                 8                10               12                   14                   16 
SO      301.2
±6.14 
278.80±
9.13 
240.60
±6.1 
214.18±8.6
2 
169.56
±9.56 
 
130.71±1
2.31 
 
94.07±12
.43 
 
50.90±10.
02 
 
31.01±5.3
8 
 
NF  
 
301.2
±6.14 
264.54±
12.29 
210.38
±12.70 
152.16±14.
87 a2 
91.32±
11.85 a3 
48.80±4.
65 a3 
23.81±4.
76 a3 
4.97±1.99 
a3 
0 a3 
5% 
CE 
298.7
±6.84 
274.49±
14.47 
205.80
±10.09 
189.32±10.
43 
108.07
±10.6 a2 
68.17±11
.18 a2 
37.68±9.
52 a2 
12.16±3.8
0 a3 
1.70±1.19 
a3 
10% 
CE  
301.2
±6.14 
250.28±
10.95 
205.54
±7.76 
118.15±13.
90 a3, b2 
57.83±
13.11 
a3, b1 
26.04±6.
65 a3, b1 
10.20±4.
58 a3 
2.62±2.05 
a3 
0a3 
n = 6 animals in each group; Values are expressed as mean ± SEM and analyzed by one way ANOVA 
followed by Tuckey post hoc test; SO, simple ointment base; CE, 80% methanol crude extract; NF, 
nitrofurazone ointment; numbers (0-16) refer days where measurement was taken following wound creation; 
0 values refer day where complete healing was achieved; a against control, b against 5 % (w/w) extract; 
1p<0.05, 2p < 0.01, 3p < 0.001. 
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Figure 4: Effects of the 80% methanol extracts on percent wound closure:   
n = 6 animals in each group; Percent wound closure increased significantly with the extracts 
across time compared to controls. Maximum closure was achieved on day 16 in 10% w/w 
extract and standard, but it took 18 days in 5% w/w extract 
B. Epithelialization period 
Time for complete epithelialization was short in extract ointments and nitrofurazone treated 
groups as compared to simple ointment treated group, (Table 3). Animals treated with 10% 
(w/w) extract and nitrofurazone showed significant decrease (p< 0.001) in epithelization 
period as evidenced by shorter period for falling of scab. Likewise, 5% (w/w) ointment 
treated group exhibited significant decrease (p= 0.001) in epithelization period as compared 
to negative control group. However, the epithelization periods of the extracts between each 
other and with standard were not statistically significant. 
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Table 3: Effects of 80% methanol extracts of Brassica carinata on period of epithelialization  
Group 
 
Epithelization period(days) 
(mean± SEM) 
Simple ointment          20.5± 0.764 
Nitrofurazone  15.33± 0.422 a3 
5%w/w crude extract 16.33± 0.615 a2 
10% w/w crude extract 14.33± 0.615 a3 
n = 6 animals in each group; Values are expressed as mean ± SEM and analyzed by one way ANOVA 
followed by Tuckey post hoc test; SO, simple ointment base; CE, 80% methanol crude extract; NF, 
nitrofurazone ointment; aagainst negative control; 1p<0.05, 2p < 0.01, 3p < 0.001. 
4.4.2 Incision wound  
A. Wound breaking strength 
Both the 10% w/w crude extract and the standard nitrofurazone showed highly significant 
breaking strength (p<0.001) compared to the negative control. The 5% w/w extract also 
showed significant effect in breaking strength (p<0.05) as compared to the negative control. 
However, 10% w/w extract was found to be significant as compared to the 5% w/w extract 
(p<0.05).  Percent tensile strength of the 10% w/w extract and nitrofurazone was significantly 
increased by about 29.8% (p< 0.001) and 31.2% (p<0.001) respectively, (Table 4). 
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Table 4:  Effects of the 80% methanol seed extract of Brassica carinata on tensile strength  
Group 
 
Tensile strength(grams)      
(mean± SEM) 
% Tensile strength  
SO          197.0±5.25 - 
NF 258.5 ± 7.2 a3, b2 31.2% 
5% CE 225.6±3.90 a1 14.5% 
10% CE 262.5 ± 10.2 a3, b 2 33.2% 
n = 6 animals in each group; Values are expressed as mean ± SEM and analyzed by one way 
ANOVA followed by Tuckey post hoc test; tensile strength was measured on the 10th post-
wounding day using continuous water flow technique; SO, simple ointment base; CE, 80% 
methanol crude extract; NF, nitrofurazone; a against negative control; b against 5% (w/w) 
extract;1 p < 0.05, 2p < 0.01, 3p < 0.001.  
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Day 0                                            day 0                                   day 0                        day o                   
 
 
  Day 8                                                    Day 8                                             Day 8                Day  8                          
   
 
     Day 16                                     Day 16                               Day 16                        Day 16     
 
Figure 5: progress of wound area contraction of negative, positive controls and 5% and 10% 
extracts in excision model 
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4.5 Wound healing activity of solvent fractions  
4.5.1 Wound contraction  
Despite differences in the results have been observed among solvent fractions, all solvent 
fractions significantly promoted wound healing when compared to the negative control as 
evidenced by shorter period of epithelialization and increased wound contraction (Table 5). 
Both 10% w/w aqueous and ethyl acetate fractions showed highly significant (p< 0.001) 
wound contraction starting from 4th   to 14th day, in comparison with the negative control 
group. In addition both 10% w/w aqueous and ethyl acetate fractions showed significant 
effect in wound contraction from 4th to 8th days when compared to 5% w/w chloroform 
fraction (p<0.01). Higher percent of wound closure was observed in 10% w/w aqueous 
fraction at day 10, 12 and 14, which was 93.5, 98.99 and 100% respectively. The 
corresponding figures for 10% w/w ethyl acetate were 92.8% (day 10), 97.1% (day 12), and 
99.4% (day 14). But standard drug showed 85.9% (day 10), 92.2 % (day 12) and 98.1% (day 
14) wound closure. 
On the other hand, both 5% w/w aqueous and ethyl acetate fractions showed significant 
wound contraction (p<0.001) starting  from 8th  day, in comparison with the negative control. 
In addition, significant effects were also seen between 5% (w/w) aqueous and ethyl acetate 
fractions and 5% w/w chloroform at day 4(p<0.05) and day 6(p<0.01).   There were not 
significant differences in wound contraction between ethyl acetate and aqueous fractions. 
The 10% w/w chloroform fraction showed significant wound area contraction from 6th day to 
10th day (p<0.01) and 12th to 18th days (p<0.001) when compared to negative control.  Faster 
rate of wound contraction was observed from 12th day onwards with maximum rate at day 12 
(95.5%), day14 (98.8%), and day 16(99.8%). There were no significant differences between 
10% w/w chloroform fraction and either 10 % w/w aqueous or ethyl acetate fraction. 
The 5% w/w chloroform fraction showed significant wound contraction at 8th day (p<0.05) 
and continued from 10th to 16th day (p<0.01) as compared to negative control. Maximum 
wound contraction was observed at day14 (96.4%), day 16(99.0%) and day18 (100%).  
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Table 5: Effects of solvent fractions of B. carinata on wound contraction 
 
  
Days Treatment groups  
SO NF CL-5% CL-10% ET-5% ET-10% Aq-5% Aq-10% 
Day0 298.69±6
.85 
298.69±6.8
5 
296.11±6.1
4 
298.69±6.8
5 
301.21±6.1
5 
301.21±6.1
5 
298.76±7.8
3 
301.21 ± 
6.15 
Day2 283.65±7
.7 
261.57±4.9
5 
268.86±6.4
9 
266.41±5.8
3 
264.02±6.1
2 
259.18±4.8
4 
263.96±4.8
3 
261.57±4.9
5 
Day4 261.76± 
8.06 
203.35±6.8
1 a2 b1 
245.25±6.8
6 
 
224.94±7.2
5 
203.35±6.8
1 a2 b1 
197.69±12.
33 a3 b1 
201.22±6.4
9 a3 b1 
195.76±13.
12 a3 b2 
Day6 201.29±7
.25 
150.85±8.4
3 
a1 
192.85±5.1
3 
 
137.77±13.
56 
a2  
133.19±7.4
5 
a2 b2 
110.29±5.7
5 
a3 b3 
133.97±11.
8 
a2 b2 
127.96±15.
39 
a3 b2 
Day8 131.49±1
6 
79.02±5.74
a1 
81.51±4.87 
a1 
74.05±6.62 
a2 
62.41±7.72
a3 
48.54±3.82 
a3 
59.53±10.9
6a3 
53.81±16.3 
a3 
Day10 95.64±17
.8 
41.47±5.97 
a2 
44.22±8.45 
a2 
36.63±7.22 
a2 
32.84±9.83 
a3 
21.393±2.4
6 a3 
30.09±6.69 
a3 
19.53±5.73 
a3 
Day12 64.76±14
.84 
23.03±3.7 
a3 
26.43±5.35
a2 
13.35±3.18 
a3 
8.5±2.31 
a3 
8.54±2.7 
a3 
6.93±1.88 
a3 
3.04±0.95 
a3 
Day14 33.62±10
.65 
5.5±1.79 
a3 
10.34±2.38 
a2 
3.4±1.29 
a3 
1.7±1.19 
a3 
1.7±1.19 
a3 
1.05±0.66 
a3 
0 
a3 
Day16 26.82±8.
53 
0.52±0.52 
a3 
2.75±1.07 
a3 
0.52±0.52 
a3 
0.52±0.52 
a3 
0 
a3 
0 
a3 
0 
a3 
Day18 16.49±5.
81 
0 
a3 
0 
a3 
0 
a3 
0 
a3 
0 
a3 
0 
a3 
0 
a3 
n = 6 animals in each group; Values are expressed as mean ± SEM and analyzed by one way ANOVA 
followed by Tuckey post hoc test; SO, simple ointment; CL, chloroform, ET, ethyl acetate, Aq, aqueous NF, 
nitrofurazone ointment; numbers (0-18) refer days where measurement was taken following wound creation; 
0 values refer day where complete healing was achieved; a against control, b against 5 % (w/w) chloroform; 
1p<0.05, 2p < 0.01, 3p < 0.001. 
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4.5.2 Epithelialization period 
Statistically significant differences in period of epithelialization have been observed between 
all fractions and simple ointment treated groups (p<0.001) except for 5% w/w chloroform 
(p<0.01). The 5% chloroform also showed significance in period of epithelialization as 
compared to ethyl acetate 5%w/w (p<0.05), ethyl acetate 10% w/w (p<0.01), aqueous 5% 
(p<0.01) and aqueous fraction 10%(p<0.001). However, the epithelization periods of 
chloroform fraction ointments between each other and with standard treated group were not 
statistically significant, (Table 6). 
Table 5: Effects of solvent fractions of Brassica carinata on period of epithelialization  
Group  Epithelization period(days) (mean± 
SEM) 
Simple ointment 20.33±0.67 
Nitrofurazone 0.2% 15.50±0.43 a3 
Chloroform fraction 5% w/w 17.17±0.40 a2 
Chloroform fraction 10% w/w 15.50±0.50 a3 
Ethyl acetate fraction  5% w/w 14.83±0.54 a3, b1 
Ethyl acetate fraction 10% w/w 14.33±0.42 a3, b2 
Aqueous fraction 5% w/w 14.33±0.33 a3, b2 
Aqueous fraction 10% w/w 13.50±0.34 a3,b3 
n = 6 animals in each group; Values are expressed as mean ± SEM and analyzed by one way 
ANOVA followed by Tuckey post hoc test; SO, simple ointment base; NF, nitrofurazone 
ointment; a against negative control; b against 5 % (w/w) chloroform; 1p<0.05, 2p < 0.01, 3p < 
0.001.  
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4.7. In vitro antibacterial activity 
Agar well diffusion antibacterial activity assay 
To explore antibacterial activity as one of the possible mechanisms for wound healing effect, 
the crude extract was subjected to this assay. As there was no information on which 
concentrations of the crude extract of Brassica carinata might produce antibacterial activity, 
initially pilot study was done by using three concentrations such as 500mg/ml, 250mg/ml and 
125 mg/ml on P. aeruginosa and S. aureus. The crude extract was not found to show 
inhibitory effect where as ciprofloxacin 5 μg/disc showed 20 mm zone of inhibition against 
P. aeruginosa and cefoxitin 30 μg/disc showed 19mm zone of inhibition against S. aureus.  
Then larger concentrations of 850mg/ml and 750 mg/ml of the extract were taken and 
subjected to the test but the extract didn’t still show bacterial growth inhibition against the 
five bacterial species with these larger concentrations, (Table 7). 
Table 6: Mean zone of inhibition of the 80% methanol extract against likely pathogens  
Concentrations Mean zone of inhibition(mm) 
Bacterial species 
S. aureus S.pyogen P. aeruginosa E.coli K.pneumoniae  
500 mg/ml NA NA NA NA NA 
750mg/ml NA NA NA NA NA 
850 mg/ml NA NA NA NA NA 
Standard antibiotics  19 28 20 23 22 
NA= no activity; standard antibiotics (ampicillin 10 μg/disc for S.pyogen , cefoxitin 30 
μg/disc for S. aureus, and ciprofloxacin 5 μg/disc for others); agar well diffusion assay was 
used to evaluate antibacterial activities at those concentrations of the extract.  Numbers for 
the standard antibiotics disc showed zone of inhibition as measured in mm. 
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5. DISCUSSION  
Wound healing involves a sequence of events which consists of coagulation, inflammation, 
granulation, wound contraction, epithelialization, and collagenation and collagen maturation 
to final scar tissue formation. Each process of wound healing is characterized by unique 
physiologic responses which are concurrent but independent to each other(13).  
Traditionally, different medicinal plants have been used for many years as topical 
preparations to promote wound healing. Majority of these plants have also been scientifically 
validated for their wound healing effects s(13, 63, 64, 80). B. carinata A Braun is one of the 
traditional medicinal plant species, the seed powder of which is used traditionally to manage 
wound (68). 
Significant rate of wound contraction and shorter period of epithelization of extracts 
compared to negative control could be due to one of the following possible reasons. First, it 
may be due to the ability of extract to enhance collagen synthesis or facilitate the 
proliferation of epithelial cells. This assumption was forwarded as it can be evidenced by 
previous report of antigenotoxic effect of the leaves of the plant. The antigenotoxic effect  of 
the plant prevents partition of the DNA and gene mutation (69) and the protection of DNA 
damage may cause to facilitate DNA synthesis followed by formation of collagen, epithelial 
cells and new blood vessels in the wound area (81).  Protection of macromolecules like DNA, 
proteins and lipids can be achieved through scavenging excess free radicals released as a 
result of oxidative stress that can be induced by a variety of environmental and chemical 
factors and natural radiation (82).  Thus, the anti genotoxicity as well as the wound healing 
activity of the plant may be due to its anti-oxidant activity.  The current assumption is also in 
line with the findings in literatures; agents that demonstrate significant antioxidant activity 
may enhance cell proliferation and wound closure by preventing damage of  DNA, lipids, 
proteins, enzymes, including free radical scavenger enzymes, the ECM and cytokines that 
speed  wound healing. The enzymes and ROS produced as a result of inflammation damage 
cells and prevent cell proliferation and wound closure by damaging DNA, lipids, proteins, 
enzymes, including free radical scavenger enzymes, the ECM and cytokines (34). 
Secondly, preliminary phytochemical screening of the crude extract revealed the presence of 
phytoconstituents like alkaloids, phenols, flavonoids, saponins, glycosides and steroids in the 
plant seed. A review on health promoting bioactive phytochemicals from Brassica genus viz 
B. nigra, B. juncea, B. oleracea and B. rapa showed  high content of poly phenols and 
flavonoids in the seeds and these phytochemicals contribute to their antioxidant and anti-
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inflammatory property (55, 59, 60, 63, 71). Particularly, Sinapic acid, an isolated phenolic 
compound and kampferol and quercetin, the flavonoids isolated from brassica vegetables 
were reported to have anti-oxidant activity (61).  
Hence, the same phytochemicals may be found in the B. carinata crude extract and 
responsible for its wound healing effect.  
Furthermore, Brassinosteroids, a group of steroidal substance, found in brassica species are 
plant growth hormones involved in cell growth, division and differentiation. They stimulated 
fibroblast proliferation and migration, and weakly induced keratinocyte proliferation. Topical 
application of brassinosteroid significantly reduced wound size and accelerated wound 
healing in treated animals in the mouse model of cutaneous wound healing (83). The crude 
extract as well as solvent fractions were positive for steroids and these steroids may play 
same wound healing effect. 
In addition to this, preliminary phytochemical screening of the crude extract revealed positive 
for glycosides.  Sinigrin is a major glucosinolate, associated with the family of glucosides 
present in the Brassicaceae family, such as the seeds of black mustard (Brassica nigra), 
Indian mustard (Brassica  juncea) and Brassica oleracea L.var. A number of studies have 
been performed on the therapeutic activities of sinigrin and revealed its anticancer, anti-
inflammatory, antifungal, antioxidant, and wound healing effects. But sinigrin when 
enzymatically hydrolyzed to its derivative isothiocyanate , it exhibits antibacterial activity 
against some bacteria (62). Therefore, sinigrin may be present in the plant seed that could be 
responsible for wound healing activity of the extracts. 
The significant increase in tensile strength of the extracts in this study may be due to 
enhanced collagen synthesis. This speculation is also evidenced by the antigenotoxic effects 
of B. carinata and its protection of DNA damage that can be caused by oxidative stress 
followed by excessive release of free radicals. Further, the present finding can be supported 
by published literature  stated that Brassica oleracea var. capitata showed maturation of the 
extracellular matrix in skin wounds of wistar rats as evidenced by significant levels of total 
collagen and glycosaminoglycans found to occur starting from 8th day compared to negative 
control. Collagen, the major protein of extracellular matrix, is the component which gives 
strength, support and integrity to the wound matrix (56). Likewise, some phytoconstituents 
like flavonoids are known to reduce lipid pero oxidation, and believed to increase the 
viability of collagen fibrils by increasing the strength of collagen fibers, increase circulation,  
prevent release of lipid peroxides and protect cell damage and  promote DNA synthesis (84).  
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Larger concentrations of the crude extract (850mg/ml, 750 mg/ml or 500 mg/ml) didn’t 
exhibit antibacterial activity against selected bacterial species in agar well diffusion assay. 
The present finding was consistent with previous report of in vitro antibacterial activities of 
B. oleracea extract against some food borne bacteria. It was reported here that B. oleracea 
was found to be inactive against S. aureus and E.coli. whereas Bacillus subtilis and B. cereus 
were found to be the most sensitive organisms (59). Lack of antibacterial activity of the crude 
extract may be explained in part by the absence of some phytochemicals like terpinoids in the 
crude extract or otherwise the phyto chemicals in the crude extract didn’t show antibacterial 
activity against bacterial species.  
In excision wound model, despite all fractions showed significant wound area contraction 
compared to the negative control at both dose levels, better activity was observed for 
10%w/w aqueous and ethyl acetate fractions as shown in table 5 and 6. Among all fractions, 
aqueous 10% w/w fraction showed the best wound healing activity as evidenced by faster rate 
of wound closure with maximum rate of closure was seen on day 12 and 14. This finding may 
indicate the phytochemicals responsible for wound healing activity are largely polar 
compounds and are found in large amount in the aqueous fraction. Phenolic compounds, 
flavonoids and glucosinolates that are found in brassica species , and which were explained 
for their antioxidant or anti-inflammatory activity, are usually polar and highly soluble in 
water because the naturally occurring glycosides sugar moieties elevate their hydrophilicity 
(85). Therefore, these compounds may contribute to facilitated wound healing in aqueous 
fraction and ethyl acetate fractions as well.  
Statistical significance in wound closure have been seen between 5% and 10% w/w 
chloroform fractions starting from 8th day in comparison with negative control. This activity 
of chloroform fractions may account to the presence of non-polar substances such as fatty 
acids as indicated in the oils of other mustard seeds. Chemical analysis of Brassica juncea 
(L.) in the previous study demonstrated the presence of significant amount of unsaturated 
fatty acids, namely oleic acid (18.2%) and linoleic acid (16.9%), erucic acid (42.0%), 
eicosenoic acid (8.8%) and others in the oil (86). Apart from this, phytochemical screening of 
chloroform fraction also indicated the presence of phenols, flavonoids, tannins, glycosides, 
alkaloids, steroids despite the type and content is unknown yet. Hence, these chemicals may 
produce combined effect of wound healing. 
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In the contrary, the aqueous as well as ethyl acetate fractions showed better activity than 
chloroform fraction. These findings may tell us that facilitated wound healing were majorly 
contributed by polar compounds or otherwise explain that polar phyto constituents are found 
in large amount in the plant seed. Also, significant differences at early days may indicate the 
aqueous and ethyl acetate fractions act to suppress excessive inflammation, free radical 
generation or enhance epithelial cell formation. 
In order to compare the findings of the present study with other findings from literatures of 
wound healing activity, ‘Evaluation of wound healing and anti-inflammatory activity of the 
rhizomes of Rumex abyssinicus J. (Polygonaceae) in mice’ showed both 5% and 10% 
extracts facilitated wound healing. The epithelialization period for the extracts was shorter; 
10% w/w extract (13.3 days) and 5% w/w (14.5) days while the negative control increased to 
17.3 days. Complete wound closure of the 10% and 5% extracts were seen faster; at 13th and 
15th days (58). Whereas the present study indicated that the epithelialization time was 14.3, 
16.3 and 20.5 days for 10%, 5% extracts and negative control respectively. Complete wound 
closure was at 16th and 18th day for 10% and 5% w/w respectively.  This comparison shows 
extracts of rhizomes of R. abyssinicus have better wound healing activity than extracts of 
B.carinata seed. This may be due to previous report of additional antibacterial activity of R. 
abyssinicus that can help promote wound healing by preventing infection or at least suppress 
microbial load on wound. On the other hand, ‘Wound healing activity of the methanol 
extracts of Clematis species indigenous to Ethiopia’ showed percent of wound contraction of 
methanol extract of C. burgensis 10% w/w was 67.9% (day 12)  and 89%(day 16) and that of 
methanol extract of C. longicauda 10% w/w  was 72% and 95% at day 12 and 16 
respectively. Even though both extracts were found to show significant effect in wound 
contraction starting from 4th day onwards when compared to negative control, complete 
wound closure for both extracts has been observed at 22th day (87). The present study 
showed that the corresponding figures in percent wound contraction of 10% w/w crude 
extract was 96.6% (day 12) and 100% (day 16). Complete wound closure in 10% w/w extract 
of B.carinata was on 16th day. This comparison can demonstrate that B.carinata seed extract 
have better wound healing activity and supports its promising wound healing potential. The 
possible reason may arise from qualitative phytochemical screening done on the methanol 
extracts of C. longicauda and C. burgensis leaves indicated presence of carbohydrates, 
proteins, tannins, saponins and flavonoids. Therefore, secondary metabolites that are found in 
the B.carinta but not in the methanol extracts of Clematis species such as phenols, steroids, 
alkaloids and glycosides could contribute to better activity of B. carinata. 
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6. CONCLUSION AND RECOMMENDATIONS  
6.1 CONCLUSION  
In the present study B. carinata crude extract and solvent fractions showed good wound 
healing activity, and the aqueous fraction showed better wound healing activity than the 
crude extracts as well as ethyl acetate or chloroform  fractions. Wound treated with crude 
extracts and solvent fractions exhibited promoted wound healing in excision and incision 
models, as evidenced by increased wound contraction, shorter epithelization time and higher 
tissue breaking strength. Hence, the present study validated the traditional folklore use of the 
plant. 
6.2 RECOMMENDATIONS  
 Chronic toxicity studies should be performed.  
 As chronic wounds such as diabetic wounds are major global burden, it is worthwhile 
to study the activity of the plant on chronic wounds.  
 Isolation and structural elucidation of active constituents should be performed to 
identify exactly the active components of the plant responsible for wound healing 
 Histopathology study should be conducted to further understand the mechanisms of 
activity 
 At last, the antibacterial activities of the plant should also be done on other bacterial 
species which were not addressed by this study.  
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